【摘要】 细胞因子释放综合征(CRS)是嵌合抗原受体T细胞疗法(CAR-T)中的一种常见药物不良反应。CAR-T疗法是通过基因工程来修饰癌症患者的T细胞,使其表达针对特异肿瘤细胞抗原的受体——嵌合抗原受体(CAR),然后再将CAR-T细胞回输入患者体内发挥抗癌作用的新型免疫疗法。但CRS发生率高且能危及患者生命,体内白细胞介素(IL-6)等细胞因子水平升高是导致CRS的主要原因。目前已上市用于控制CRS的IL-6靶向药较少。为此,本文就近年来以IL-6等靶点为主的、控制CRS的生物药物及其在CRS中的使用情况做一综述。更多还原

【Abstract】 Cytokine release syndrome( CRS),a common adverse drug reaction in chimeric antigen receptor T cell therapy( CAR-T),is a newly immune anti-cancer regime,which modifies T cells extracted from patients into CAR-T cells through genetic engineering and then gives CAR-T back to patients for cancer control. CRS is widely concerned due to its high incidence and life-threatening risk. Studies have shown that elevated levels of interleukin 6( IL-6) and other cytokines in vivo are the major causes of CRS,but very few IL-6 targeted drugs are currently available to control CRS. Therefore,in order to get a better control of CRS in CAR-T clinical treatment,this review will summarize some agents with IL-6 as the target and their applications reported in CRS management.更多还原